Beranda › Nefritis Lupus › Pennsylvania
Uji klinis Nefritis Lupus di Pennsylvania
7 studi untuk Nefritis Lupus mencari peserta di lokasi di Pennsylvania.
Kota di Pennsylvania
Teks studi resmi (Bahasa Inggris)
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- Temple University, Philadelphia
Menerima pesertaFase 2
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05268289CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
- Children's Hospital of Philadelphia, Philadelphia
Menerima pesertaFase 1/2
Usia 10 hingga 29 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06839976A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- Fox Chase Cancer Center- Temple BMT, Philadelphia
Menerima pesertaFase 2
Usia 16 hingga 70 · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07328581VIBRANT: VIB4920 for Active Lupus Nephritis
- Penn State Health Milton S. Hershey Medical Center: Division of Rheumatology, Hershey
- Temple University, Lewis Katz School of Medicine, Department of Medicine: Nephrology, Philadelphia
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT05201469RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Children's Hospital of Philadelphia, Philadelphia
Menerima pesertaFase 1/2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT06121297PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
- Rheumatic Disease Associates, Ltd., Willow Grove
Menerima pesertaFase 4
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT07611214A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Jefferson Einstein Hospital Philadelphia, Philadelphia
Menerima pesertaFase 1
Usia 12 hingga 70 · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT06308978Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.